Tempest Therapeutics, INC

Tempest Therapeutics reported Q2 2026 financial results, highlighting a new development collaboration for TPST-4003, positive interim data for TPST-2003, and strategic board appointments.

Tempest Therapeutics has entered into a $50 million purchase agreement with Lincoln Park Capital Fund, LLC, providing a flexible equity financing option.

Tempest Therapeutics has adjourned its special meeting of stockholders to allow for additional voting time on a proposed amendment to its Certificate of Incorporation.

Tempest Therapeutics and Hebei Senlang Biotechnology have entered into a collaboration agreement to develop Tempest's TPST-4003 CAR-T candidate, initiating with an investigator-initiated trial in China.

Tempest Therapeutics has appointed two new independent directors and a new Principal Financial Officer to address board vacancies and leadership transitions.

Tempest Therapeutics announced the resignation of board member Ms. Simantov effective May 23, 2026.

Tempest Therapeutics' Q2 2026 Form 10-Q reveals significant financial challenges, including substantial operating losses and a critical cash position, while also highlighting progress in its CAR-T therapy development.

Tempest Therapeutics and Factor Bioscience Inc. have entered into a letter agreement to modify payment obligations under their Master Services Agreement, impacting future payments and a prior deposit.

Tempest Therapeutics reports significant cash burn and a going concern warning, while advancing key oncology programs and exploring strategic alternatives.

Tempest Therapeutics reports Q2 2025 financial results, highlighting ongoing strategic review, workforce reduction, and progress in its clinical-stage oncology pipeline despite significant operating losses and going concern doubts.

Tempest Therapeutics reports Q1 2025 results, initiates strategic review, and reduces workforce amid going concern uncertainty.

Tempest Therapeutics reports its third quarter 2024 financial results and provides an update on its clinical programs, including the planned pivotal Phase 3 trial for amezalpat in liver cancer.

Tempest Therapeutics closed a share-funded CAR‑T asset deal, reported striking early multiple myeloma data, and outlined 2026 milestones, but flagged a going‑concern risk with just $7.7M in cash and reliance on an uncertain funding commitment.

Tempest Therapeutics files an amendment to its annual report on Form 10-K to include required information on directors, executive officers, corporate governance, and updated certifications.

Tempest Therapeutics highlights positive clinical trial results for amezalpat and TPST-1495, alongside strategic plans for pipeline expansion and business development in its 2024 10-K filing.

Tempest Therapeutics details its common and preferred stock structure, including a recently adopted stockholder rights plan, in its annual 10-K filing.

Director John D. Yee was granted 25,000 stock options in Tempest Therapeutics, Inc. as part of a standard equity compensation package.

Director William Drake Richey was granted 25,000 stock options in Tempest Therapeutics, Inc. as part of a standard equity incentive.

Tempest Therapeutics Corporate Controller Justin Trojanowski acquired employee stock options, with vesting scheduled to begin in March 2027.

Tempest Therapeutics' Chief Financial Officer, Nicholas Maestas, was granted employee stock options for 140,000 shares.

Tempest Therapeutics' CEO and President, Matthew Angel, acquired 231,482 shares of common stock for $2.16 per share, signaling strong insider confidence.

Tempest Therapeutics CEO and President Matthew Angel was granted 269,621 employee stock options with an exercise price of $2.38, vesting over four years.

Tempest Therapeutics is holding a special meeting of stockholders on July 27, 2026, to vote on proposed amendments to its Certificate of Incorporation.

Tempest Therapeutics is holding a special meeting on June 18, 2026, to seek stockholder approval for the issuance of shares related to warrant exercises, crucial for Nasdaq compliance and company operations.

Tempest Therapeutics announces a strategic asset acquisition of CAR-T cell therapies from Erigen and Factor Bioscience, securing new funding and appointing a new CEO, subject to stockholder approval.

Tempest Therapeutics, Inc. announced the acquisition of a portfolio of CAR T-cell therapy assets from Erigen LLC and Factor Bioscience Inc. in exchange for 8.27 million shares of its common stock.

Tempest Therapeutics is asking stockholders to approve a reverse stock split, ranging from 1-for-2 to 1-for-15, to potentially improve the marketability and liquidity of its common stock.

Tempest Therapeutics, Inc. announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, with voting open until June 12, 2024, covering director elections, executive compensation, and auditor ratification.

Tempest Therapeutics, a clinical-stage biotechnology company, filed an S-1 registration statement for the resale of 1,172,414 common shares by a selling stockholder, issuable upon warrant exercise.

Matthew Angel, CEO of Tempest Therapeutics, significantly increased his beneficial ownership to 37.4% through recent asset and securities purchase agreements.

Tempest Therapeutics CEO Matthew Angel has significantly increased his beneficial ownership in the company to 35.9% following an asset purchase agreement.

Versant Venture Capital funds filed an amended Schedule 13D, updating their beneficial ownership in Tempest Therapeutics, Inc. due to dilution from recent share sales.

Versant Venture Capital and related entities have filed an amended Schedule 13D, disclosing a decrease of over one percent in their aggregate beneficial ownership of Tempest Therapeutics, Inc. common stock due to dilution from the issuer's recent share sales.

Sabby Management, Hal Mintz, and Sabby Volatility Warrant Master Fund report a 9.9% beneficial ownership stake in Tempest Therapeutics, Inc.